

Technology Advisory Committee B Interests Register

Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

Publication Date: 09/06/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr James Fotheringham	TA Committee B Member	Direct – financial	Received speaker fees from Novartis for chairing an industry symposium, relating to kidney transplantation.	NA	18/03/2021	NA	It was agreed that this declaration did not prevent Dr Fotheringham from participating in this section of the meeting.
Dr James Fotheringham	TA Committee B Member	Indirect interest	Dr Fotheringham’s employer, University of Sheffield, received funding from Novartis to author a NICE Briefing Book to inform a NICE Scientific Advisory meeting. The Briefing Book related to kidney transplantation.	NA	18/03/2021	NA	It was agreed that this declaration did not prevent Dr Fotheringham from participating in this section of the meeting.
Dr Nicholas Latimer	TA Committee B Member	Direct - financial	Received payment by Merck Serono to present methods for modelling treatment sequences at ISPOR Webinar. The presentation was unrelated to any specific drug or disease area.	NA	13/11/2020	NA	It was agreed that this declaration did not prevent Dr Latimer from participating in this section of the meeting.

Dr Eli Silber	Clinical Expert	Indirect interests	Dr Silber's employer, King's College Hospital, received funding for participating in trials of this drug. Dr Silber derived no personal benefit from any of the work undertaken.	NA	09/10/2019	NA	It was agreed that this declaration would not prevent Dr Silber from providing expert advice to the committee.
---------------	-----------------	--------------------	--	----	------------	----	--